Ascendis Pharma A/S (NASDAQ:ASND) Releases Earnings Results, Misses Expectations By $0.58 EPS

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58), Zacks reports. The firm had revenue of $290.38 million for the quarter, compared to analysts’ expectations of $285.35 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• Q4 Europats revenue was EUR 187 million (full-year EUR 477 million), with >5,300 U.S. patients prescribed by ~2,400 prescribers and a roughly 70% insurance approval rate, supporting continued rollout and expansion.
• SKYTROFA generated Q4 revenue of EUR 53 million (FY 2025: EUR 206 million), holds ~7% U.S. market share, and Ascendis has initiated a phase 3 basket trial to pursue multiple additional growth disorder indications.
• TransCon CNP (achondroplasia) NDA is under FDA review with a PDUFA date of February 28, 2026, and Phase 2 combination data showed ~3–4x greater linear growth versus monotherapies plus meaningful improvements in body proportionality and arm span.
• Financials: full-year revenue was EUR 720 million with year-end cash of EUR 616 million and FY operating expenses of EUR 761 million; management forecasts ~EUR 500 million operating cash flow in 2026 and an aspirational EUR 5 billion in annual product revenue by 2030, which depend on approvals, launches and execution.
• Pipeline & competition: company is advancing once-weekly TransCon PTH and a once-monthly TransCon semaglutide collaboration, while management downplayed rivals like Encaleret and warned about safety/ specificity risks for some FGFR-targeting programs — competitive uncertainty remains.

Ascendis Pharma A/S Price Performance

Shares of ASND traded down $3.16 on Friday, reaching $214.94. The company’s stock had a trading volume of 378,271 shares, compared to its average volume of 731,460. The stock’s 50 day simple moving average is $214.64 and its two-hundred day simple moving average is $204.49. The stock has a market capitalization of $13.32 billion, a P/E ratio of -48.85 and a beta of 0.44. Ascendis Pharma A/S has a 12-month low of $124.06 and a 12-month high of $242.00.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price target on the stock. Bank of America upped their target price on Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Wall Street Zen cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Royal Bank Of Canada upped their price target on Ascendis Pharma A/S from $245.00 to $250.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $256.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $284.00.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers purchased a new position in Ascendis Pharma A/S in the second quarter worth about $552,000. Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 55 shares during the period. Daiwa Securities Group Inc. lifted its position in Ascendis Pharma A/S by 66.2% in the second quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock worth $645,000 after buying an additional 1,488 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Ascendis Pharma A/S by 83.4% in the second quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock worth $34,700,000 after buying an additional 91,412 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Ascendis Pharma A/S during the second quarter valued at $897,000.

Key Headlines Impacting Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Earnings call highlighted growth momentum and strong YORVIPATH sales, and management pointed to commercial execution and revenue expansion as key drivers. Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Wedbush raised its price target to $273 and kept an Outperform rating, implying meaningful upside from current levels and signaling analyst confidence in the revenue trajectory. ASND price target raised by Wedbush
• Positive Sentiment: Brokerage coverage remains constructive — the consensus rating is around “Buy”, which supports investor sentiment and may limit downside from the earnings miss. Ascendis given average ‘Buy’ rating
• Neutral Sentiment: Several analyst write-ups and investor pieces evaluate Ascendis’s momentum and strategy; these provide context but don’t change near-term fundamentals immediately. Analysts Offer Insights on Ascendis
• Neutral Sentiment: Investor-focused pieces (AAII, Seeking Alpha) discuss technical momentum and longer-term thesis; useful for positioning but not immediate catalysts. Does ASND Have Momentum?
• Neutral Sentiment: Reported short-interest data in the wires appears anomalous (zeros/NaN) and should be treated with caution; no clear short-squeeze signal from the available data.
• Negative Sentiment: Q4 EPS missed badly — reported loss per share of $0.64 vs. consensus -$0.06 — a significant earnings miss that pressured sentiment despite a slight revenue beat. Q4 earnings miss details
• Negative Sentiment: Competitive news: reports that BridgeBio’s moves are reshaping the achondroplasia competitive landscape weighed on peers including Ascendis, raising execution and market-share risk in the key indication. BridgeBio impact on achondroplasia market

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.